Literature DB >> 19670423

CD4 T cells promote tissue inflammation via CD40 signaling without de novo activation in a murine model of liver ischemia/reperfusion injury.

Xiuda Shen1, Yue Wang, Feng Gao, Feng Ren, Ronald W Busuttil, Jerzy W Kupiec-Weglinski, Yuan Zhai.   

Abstract

UNLABELLED: Although the role of CD4 T cells in tissue inflammation and organ injury resulting from ischemia and reperfusion injury (IRI) has been well documented, it remains unclear how CD4 T cells are activated and function in the absence of a specific antigen (Ag). We used a murine liver warm IRI model to determine first whether de novo Ag-specific CD4 T cell activation was required and then what its functional mechanism was. The critical role of CD4 T cells in liver immune activation against ischemia and reperfusion (IR) was confirmed in CD4 knockout mice and CD4 depleted wild-type mice. Interestingly, the inhibition of CD4 T cell activation without target cell depletion failed to protect livers against IRI, and this suggested that T cells function in liver IRI without Ag-specific de novo activation. To dissect the T cell functional mechanism, we found that CD154 blockade, but not interferon gamma (IFN-gamma) neutralization, inhibited local immune activation and protected livers from IRI. Furthermore, agonist anti-CD40 antibodies restored liver IRI in otherwise protected CD4-deficient hosts. Finally, fluorescence-activated cell sorting analysis of liver CD4 T cells revealed the selective infiltration of effector cells, which constitutively expressed a higher level of CD154 in comparison with their peripheral counterparts. IR triggered a significant liver increase in CD40 expression but not CD154 expression, and macrophages responded to toll-like receptor 4 and type I IFN stimulation to up-regulate CD40 expression.
CONCLUSION: These novel findings provide evidence that CD4 T cells function in liver IRI via CD154 without de novo Ag-specific activation, and innate immunity-induced CD40 up-regulation may trigger the engagement of CD154-CD40 to facilitate tissue inflammation and injury.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19670423      PMCID: PMC2805281          DOI: 10.1002/hep.23153

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  43 in total

1.  Ability of a nondepleting anti-CD4 antibody to inhibit Th2 responses and allergic lung inflammation is independent of coreceptor function.

Authors:  L Li; M Crowley; A Nguyen; D Lo
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

2.  Allograft rejection by primed/memory CD8+ T cells is CD154 blockade resistant: therapeutic implications for sensitized transplant recipients.

Authors:  Yuan Zhai; Lingzhong Meng; Feng Gao; Ronald W Busuttil; Jerzy W Kupiec-Weglinski
Journal:  J Immunol       Date:  2002-10-15       Impact factor: 5.422

3.  Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure.

Authors:  M J Burne; F Daniels; A El Ghandour; S Mauiyyedi; R B Colvin; M P O'Donnell; H Rabb
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

Review 4.  The T cell as a bridge between innate and adaptive immune systems: implications for the kidney.

Authors:  Hamid Rabb
Journal:  Kidney Int       Date:  2002-06       Impact factor: 10.612

5.  Involvement of receptor-interacting protein 2 in innate and adaptive immune responses.

Authors:  Arnold I Chin; Paul W Dempsey; Kevin Bruhn; Jeff F Miller; Yang Xu; Genhong Cheng
Journal:  Nature       Date:  2002-03-14       Impact factor: 49.962

6.  Nondepleting anti-CD4 monoclonal antibody prevents diabetes and blocks induction of insulin autoantibodies following insulin peptide B:9-23 immunization in the NOD mouse.

Authors:  Edwin Liu; Hiroaki Moriyama; Johanna Paronen; Norio Abiru; Dongmei Miao; Liping Yu; Robert M Taylor; George S Eisenbarth
Journal:  J Autoimmun       Date:  2003-11       Impact factor: 7.094

7.  CD154-CD40 T-cell costimulation pathway is required in the mechanism of hepatic ischemia/reperfusion injury, and its blockade facilitates and depends on heme oxygenase-1 mediated cytoprotection.

Authors:  Xiu-Da Shen; Bibo Ke; Yuan Zhai; Farin Amersi; Feng Gao; Dean M Anselmo; Ronald W Busuttil; Jerzy W Kupiec-Weglinski
Journal:  Transplantation       Date:  2002-08-15       Impact factor: 4.939

8.  Stat4 and Stat6 signaling in hepatic ischemia/reperfusion injury in mice: HO-1 dependence of Stat4 disruption-mediated cytoprotection.

Authors:  Xiu-Da Shen; Bibo Ke; Yuan Zhai; Feng Gao; Dean Anselmo; Charles R Lassman; Ronald W Busuttil; Jerzy W Kupiec-Weglinski
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

9.  Recipient T cells mediate reperfusion injury after lung transplantation in the rat.

Authors:  Marc de Perrot; Kevin Young; Yumiko Imai; Mingyao Liu; Thomas K Waddell; Stefan Fischer; Li Zhang; Shaf Keshavjee
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

10.  Type I, but not type II, interferon is critical in liver injury induced after ischemia and reperfusion.

Authors:  Yuan Zhai; Bo Qiao; Feng Gao; Xiuda Shen; Andrew Vardanian; Ronald W Busuttil; Jerzy W Kupiec-Weglinski
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

View more
  48 in total

1.  Hydrogen sulfide augments survival signals in warm ischemia and reperfusion of the mouse liver.

Authors:  Shingo Shimada; Moto Fukai; Kenji Wakayama; Takahisa Ishikawa; Nozomi Kobayashi; Taichi Kimura; Kenichiro Yamashita; Toshiya Kamiyama; Tsuyoshi Shimamura; Akinobu Taketomi; Satoru Todo
Journal:  Surg Today       Date:  2014-11-02       Impact factor: 2.549

2.  Transcriptional analysis of infiltrating T cells in kidney ischemia-reperfusion injury reveals a pathophysiological role for CCR5.

Authors:  Gang Jee Ko; Douglas Linfert; Hye Ryoun Jang; Elizabeth Higbee; Tonya Watkins; Chris Cheadle; Manchang Liu; Lorraine Racusen; Dmitry N Grigoryev; Hamid Rabb
Journal:  Am J Physiol Renal Physiol       Date:  2011-12-07

3.  Interleukin-22: implications for liver ischemia-reperfusion injury.

Authors:  Paul J Chestovich; Yoichiro Uchida; William Chang; Mark Ajalat; Charles Lassman; Robert Sabat; Ronald W Busuttil; Jerzy W Kupiec-Weglinski
Journal:  Transplantation       Date:  2012-03-15       Impact factor: 4.939

Review 4.  Ischemia and reperfusion--from mechanism to translation.

Authors:  Holger K Eltzschig; Tobias Eckle
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

5.  Serum cytokine profiles associated with early allograft dysfunction in patients undergoing liver transplantation.

Authors:  Benjamin H Friedman; Joshua H Wolf; Liqing Wang; Mary E Putt; Abraham Shaked; Jason D Christie; Wayne W Hancock; Kim M Olthoff
Journal:  Liver Transpl       Date:  2012-02       Impact factor: 5.799

6.  Parenchymal expression of CD40 exacerbates adenovirus-induced hepatitis in mice.

Authors:  Jiabin Yan; Zuliang Jie; Lifei Hou; Joao L Wanderley; Lynn Soong; Shalini Gupta; Suimin Qiu; Tehsheng Chan; Jiaren Sun
Journal:  Hepatology       Date:  2011-05       Impact factor: 17.425

7.  Sotrastaurin, a protein kinase C inhibitor, ameliorates ischemia and reperfusion injury in rat orthotopic liver transplantation.

Authors:  N Kamo; X-D Shen; B Ke; R W Busuttil; J W Kupiec-Weglinski
Journal:  Am J Transplant       Date:  2011-08-30       Impact factor: 8.086

8.  Ag-specific CD4 T cells promote innate immune responses in liver ischemia reperfusion injury.

Authors:  Jianhua Rao; Feng Cheng; Shikun Yang; Yuan Zhai; Ling Lu
Journal:  Cell Mol Immunol       Date:  2018-06-15       Impact factor: 11.530

Review 9.  Ischaemia-reperfusion injury in liver transplantation--from bench to bedside.

Authors:  Yuan Zhai; Henrik Petrowsky; Johnny C Hong; Ronald W Busuttil; Jerzy W Kupiec-Weglinski
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-12-11       Impact factor: 46.802

10.  Early cytokine signatures of ischemia/reperfusion injury in human orthotopic liver transplantation.

Authors:  Rebecca A Sosa; Ali Zarrinpar; Maura Rossetti; Charles R Lassman; Bita V Naini; Nakul Datta; Ping Rao; Nicholas Harre; Ying Zheng; Roberto Spreafico; Alexander Hoffmann; Ronald W Busuttil; David W Gjertson; Yuan Zhai; Jerzy W Kupiec-Weglinski; Elaine F Reed
Journal:  JCI Insight       Date:  2016-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.